Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    MEDI4736-MM-001
Previous Study | Return to List | Next Study

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Celgene
Information provided by (Responsible Party):
Celgene Identifier:
First received: November 25, 2015
Last updated: January 31, 2017
Last verified: January 2017
This is a multicenter, multicountry, open-label, Phase 1b study for dose finding as well as parallel cohort dose expansion(s) to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with pomalidomide (POM) with or without low dose dex in subjects with Relapsed and Refractory Multiple Myeloma (RRMM). The study will consist of a dose-finding portion as well as a parallel dose expansion portion to determine the optimal dose and regimen.

Condition Intervention Phase
Multiple Myeloma
Drug: Durvalumab
Drug: Pomalidomide
Drug: Dexamethasone
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)

Resource links provided by NLM:

Further study details as provided by Celgene:

Primary Outcome Measures:
  • Dose-limiting Toxicities (DLTs) [ Time Frame: Approximately 1 month ]
    Number of participants with DLTs in the first cycle of treatment

Secondary Outcome Measures:
  • Adverse Events (AEs) [ Time Frame: Up to approximately 2 year ]
    Number of participants with adverse events

  • Overall response rate (ORR) [ Time Frame: Up to approximately 2 year ]
    Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria

  • Time to response (TTR) [ Time Frame: Up to approximately 2 year ]
    Time to response (for responders only, per IMWG criteria) is calculated as the time from the first date of dosing of study treatment to the first date of documented response (partial response (PR) or better).

  • Duration of response (DOR) [ Time Frame: Up to approximately 2 year ]
    Is defined as time from the earliest date of documented response (partial response (PR) or better) to the earliest date when disease progression was confirmed

  • Pharmacokinetics- Cmax [ Time Frame: Up to approximately 1 year ]
    Maximum observed concentration

  • Pharmacokinetics- AUC [ Time Frame: Up to approximately 1 year ]
    Area under the concentration-time curve

  • Pharmacokinetics- Tmax [ Time Frame: Up to approximately 1 year ]
    Time to maximum concentration

  • Pharmacokinetics- t1/2 [ Time Frame: Up to approximately 1 year ]
    Terminal elimination half-life

  • Pharmacokinetics- CL/F [ Time Frame: Up to approximately 1 year ]
    Apparent total body clearance

  • Pharmacokinetics- Vz/F [ Time Frame: Up to approximately 1 year ]
    Volume of distribution

Estimated Enrollment: 138
Study Start Date: January 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Durvalumab monotherapy
Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
Drug: Durvalumab
Other Name: MEDI4736
Experimental: Durvalumab + pomalidomide (POM)
IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
Drug: Durvalumab
Other Name: MEDI4736
Drug: Pomalidomide
Experimental: Durvalumab + pomalidomide (POM) + dexamethasone (dex)
IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
Drug: Durvalumab
Other Name: MEDI4736
Drug: Pomalidomide Drug: Dexamethasone


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has a confirmed diagnosis of active multiple myeloma and measurable disease.
  • Must have undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy
  • Must have failed last line of treatment (refractory to last line of treatment).
  • Must have achieved at least a stable disease (SD) for at least 1 cycle of treatment to at least 1 prior anti-myeloma regimen before developing Progressive disease (PD) (relapsed)
  • Prior anti-myeloma treatments must have included a lenalidomide AND proteasome inhibitor alone or in combination.
  • Has performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

Exclusion Criteria:

  • Has non-secretory or oligosecretory multiple myeloma
  • Has had prior anti-myeloma therapy within 2 weeks prior to study Day 1
  • Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
  • Has received previous therapy with pomalidomide and did not achieve at least a stable disease
  • Has received prior therapy with an anti-programmed cell death 1 receptor (anti-PD-1), antiprogrammed death-ligand 1 (anti-PD-L1), antiprogrammed death-ligand 2 (anti-PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Has received prior treatment with a monoclonal antibody within 5 half-lives of Study Day 1
  • Has received investigational agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1
  • Has received live, attenuated vaccine within 30 days prior to Study Day 1
  • Had rash ≥ Grade 3 during prior thalidomide, lenalidomide, or pomalidomide therapy
  • Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dex
  • Has peripheral neuropathy ≥ Grade 2
  • Has a known additional malignancy that is progressing or requires active treatment (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
  • Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
  • Has a prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years (with the exception Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer [T1a or T1b] or prostate cancer that is curative)
  • Has clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS multiple myeloma
  • Has clinically significant cardiac disease
  • Is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during the participation in the study
  • Is a current smoker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02616640

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599

  Show 35 Study Locations
Sponsors and Collaborators
Study Director: Lars Sternas, MD, PhD Celgene Corporation
  More Information

Responsible Party: Celgene Identifier: NCT02616640     History of Changes
Other Study ID Numbers: MEDI4736-MM-001
Study First Received: November 25, 2015
Last Updated: January 31, 2017

Keywords provided by Celgene:
Multiple Myeloma
Pomalidomide (POM)
Dexamethasone (DEX)

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on April 28, 2017